-
Nov 19, 2024 | 00726-6/fulltext&sz=64)
thelancet.com | Angelo Roberto Raccagni |Vita-Salute San Raffaele |Sara Diotallevi |Elena Bruzzesi
Bacterial sexually transmitted infections (STIs) are a considerable burden among people with HIV and users of HIV pre-exposure prophylaxis (PrEP).1–3 Doxycycline post-exposure prophylaxis (DoxyPEP) is a pharmacological intervention, the efficacy of which in reducing bacterial STIs, particularly syphilis and chlamydia, has been confirmed in several clinical trials.4–9 In this study, we aimed to evaluate the uptake of DoxyPEP among men who have sex with men (MSM) in Milan, Italy, its...
-
Nov 18, 2024 | 
mdpi.com | Angelo Roberto Raccagni |Riccardo Lolatto |Flavia Passini |Lovel Lisac
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Sep 12, 2024 | 
sti.bmj.com | Angelo Roberto Raccagni |Francesca Saluzzo |Virginia Batignani |Alma Zinola
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Jun 17, 2024 | 
sti.bmj.com | Angelo Roberto Raccagni |Elena Bruzzesi |Antonella Castagna |Silvia Nozza
Doxycycline postexposure prophylaxis may delay seroconversion in incident syphilis Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Apr 26, 2024 | 
mdpi.com | Angelo Roberto Raccagni |Alessandro Mancon |Sara Diotallevi |Riccardo Lolatto
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 18, 2023 | 
mdpi.com | Angelo Roberto Raccagni |Elena Bruzzesi |Chiara Maci |Martina Ranzenigo
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 18, 2023 | mdpi.com | Angelo Roberto Raccagni |Elena Bruzzesi |Chiara Maci |Martina Ranzenigo
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Dec 7, 2023 | 00741-7/fulltext&sz=64)
thelancet.com | Martina Bottanelli |Vita-Salute San Raffaele |Emanuela Messina |Angelo Roberto Raccagni
In a recent study in The Lancet Infectious Diseases, Nicolò Moschetta and colleagues compared the neutralising antibody response of individuals at 6 months after mpox (formerly known as monkeypox) infection or Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccination, finding that people receiving vaccination had lower concentrations of mpox neutralising antibodies than individuals with mpox infection. 1Moschetta N Raccagni AR Bianchi M et al.
-
Oct 11, 2023 | 00571-6/abstract&sz=64)
thelancet.com | Angelo Roberto Raccagni |Ospedale L. Sacco |Sara Diotallevi |Maria Rita Gismondo
1Thornhill JP Barkati S Walmsley S et al. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med. 387: 679-691Over 80 000 cases of mpox (formerly known as monkeypox) infection have been confirmed since May 2022., 2Girometti N Byrne R Bracchi M et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis.
-
Aug 24, 2023 | 
mdpi.com | Angelo Roberto Raccagni |Riccardo Lolatto |Flavia Passini |Sara Diotallevi
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticleby 1,†, 1,*,†, 2, 2, 1, 1, 1, 1, 1, 1,2 and 1,2 1Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy2Infectious Diseases Unit, San Raffaele Scientific Institute, 20132 Milan, Italy*Author to whom correspondence should be addressed. †These authors contributed equally to this work.
